P refrontal cortex (PFC), a brain area highly associated with the control of cognition and emotion (1), is one of the most prominent regions affected by schizophrenia (2, 3). Schizophrenics often exhibit deficits in cognitive tasks requiring working memory subserved by PFC circuits (4). Despite the unclear etiology of schizophrenia, aberrations of several neurotransmitter systems have been implicated in this disorder. Among them, dysfunctions of the dopaminergic and glutamatergic systems in PFC are considered to be major contributing factors to the pathophysiology of schizophrenia (5).
P refrontal cortex (PFC), a brain area highly associated with the control of cognition and emotion (1) , is one of the most prominent regions affected by schizophrenia (2, 3) . Schizophrenics often exhibit deficits in cognitive tasks requiring working memory subserved by PFC circuits (4) . Despite the unclear etiology of schizophrenia, aberrations of several neurotransmitter systems have been implicated in this disorder. Among them, dysfunctions of the dopaminergic and glutamatergic systems in PFC are considered to be major contributing factors to the pathophysiology of schizophrenia (5) .
It has long been recognized that dopamine receptors play a key role in the modulation of PFC working memory functions (1) . Dopamine depletion in PFC results in impaired performances in PFC cognitive tasks, and these deficits can be ameliorated by the mixed dopamine receptor agonist apomorphine (6) . The role of D 1 receptors in this process has been extensively explored. Iotophoresis of low concentrations of D 1 receptor antagonists enhances memory-related neuronal responses in monkeys performing challenging working memory tasks (7) . On the other hand, administration of low, but not high, doses of D 1 receptor agonists improves spatial working memory performance (8) . These results suggest that optimal levels of D 1 receptor stimulation are important for maintaining PFC functions.
Increasing evidence has suggested that, in addition to dopaminergic dysfunction, hypofunction of N-methyl-D-aspartate receptors (NMDARs) also plays a key role in schizophrenia (9) . Administration of noncompetitive NMDAR antagonists in humans and animals produces behavioral symptoms that are remarkably similar to schizophrenia (10, 11) . Mutant mice expressing 5% of the normal level of NR1 (12) exhibit a series of schizophrenia-like behaviors, which are ameliorated by administration of antipsychotic drugs that target dopamine receptors (12) . To begin to understand how the ''dopamine hypothesis'' and ''glutamate hypothesis'' of schizophrenia may be mechanistically linked, we examined the interactions between D 1 and NMDARs in PFC pyramidal neurons. A previous study has shown that dopamine D 1 signaling can be regulated by NMDAR activation (13) . In this study, we provide evidence showing that NMDAR activity can be regulated by dopamine D 1 signaling.
Materials and Methods
Acute-Dissociation Procedure. PFC neurons from young adult (3-5 weeks postnatal) rats were acutely dissociated by using procedures similar to those described in ref. 14 (version 8) with a DigiData 1320 series interface (Axon Instruments). Electrode resistances were typically 2-4 M⍀ in the bath. After seal rupture, series resistance (4-10 M⍀) was compensated (70-90%) and periodically monitored. The cell membrane potential was held at Ϫ60 mV. NMDA (500 M) was applied for 2 s every 30 s to minimize desensitization-induced decrease of current amplitude. The application of NMDA evoked a partially desensitizing inward current. Steady-state current amplitudes were measured at the end of a 2-s application of NMDA for generating the plot as a function of time and drug application. Drugs were applied with a gravity-fed ''sewer pipe'' system. The array of application capillaries (Ϸ150 m i.d.) was positioned a few hundred microns from the cell under study. Solution changes were effected Abbreviations: AKAP, A-kinase anchoring protein; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetate; CaM, calmodulin; CDZ, calmidazolium; CsA, cyclosporin A; MLCK, myosin light chain kinase; NMDA, N-methyl-D-aspartate; NMDAR, NMDA receptor; OA, okadaic acid; PFC, prefrontal cortex; PKA, protein kinase A; PP1, protein phosphatase 1. ‡ To whom correspondence should be addressed. E-mail: zhenyan@buffalo.edu.
by the SF-77B fast-step solution stimulus delivery device (Warner Instruments, Hamden, CT).
Dopamine receptor ligands SKF81297 and SCH23390 (Sigma), as well as second messenger reagents PKI 6 -22 , myristoylated PKI 14 -22 , okadaic acid (OA), calmodulin (CaM), calmidazolium (CDZ), myosin light chain kinase (MLCK) peptide, KN-93, cyclosporin A (CsA), PKC 19 -36 , bisindolylmaleimide I, U73122, heparin, wortmannin, and genistein (Calbiochem) were made up as concentrated stocks and stored at Ϫ20°C. The final DMSO concentration in all applied solutions was Ͻ0.1%. Stocks were thawed and diluted immediately before use. The amino acid sequence for the protein phosphatase 1 (PP1)-anchoring inhibitory peptide Gm[63-75] is GRRVSFADNFGFN.
Data analyses were performed with AXOGRAPH (Axon Instruments), KALEIDAGRAPH (Albeck, Reading, PA), ORIGIN 6 (OriginLab, Northampton, MA), and STATVIEW (Abacus Concepts, Berkeley, CA). For analysis of statistical significance, MannWhitney U tests were performed to compare the current amplitudes in the presence or absence of agonists. ANOVA tests were performed to compare the differential degrees of current modulation between groups subjected to different treatment.
Results

Activation of D1 Receptors Enhances NMDA-Evoked Currents in Dis-
sociated PFC Pyramidal Neurons. To test the potential impact of D 1 receptors on NMDA signaling, we examined the effect of SKF81297, a selective D 1 receptor agonist, on NMDAR-mediated currents in acutely isolated PFC pyramidal neurons. As shown in Fig. 1 A and B, application of NMDA (500 M) evoked a partially desensitizing inward current, and SKF81297 (10 M) caused a potent and reversible increase in the amplitude of NMDA-evoked currents in the PFC pyramidal neuron. Moreover, the enhancing effect of SKF81297 was most prominent in the steady-state component of NMDA-evoked currents, suggesting a suppression of desensitization or inactivation of NMDARs. In a sample of PFC pyramidal neurons we tested, SKF81297 produced a 19.8 Ϯ 5.4% (n ϭ 98, P Ͻ0.01, MannWhitney) enhancement of steady-state NMDAR currents (I ss ).
To verify that D 1 receptors were responsible for the modulation seen with SKF81297, we examined the ability of SCH23390, a selective D 1 receptor antagonist, to prevent the action of SKF81297. As shown in Fig. 1C , SKF81297 (10 M) produced a reversible enhancement of the steady-state NMDAR current in the PFC neuron, and this effect was greatly reduced by SCH23390 (10 M). In a sample of cells we examined, SKF81297 had a significantly (P Ͻ0.005, ANOVA) smaller effect on steady-state NMDAR currents in the presence of SCH23390 (9.8 Ϯ 3.8%, n ϭ 4), compared to the effect of SKF81297 in the absence of SCH23390 (22.3 Ϯ 2.0%, n ϭ 4). These results suggest We next examined the signal transduction pathway mediating the D 1 potentiation of NMDAR currents in PFC pyramidal neurons. The ''classical'' signaling cascade of D 1 receptors is to stimulate adenylate cyclase and cAMP formation. The D 1 -induced activation of PKA could directly modulate NMDAR currents through increased phosphorylation of NR1 subunits on the PKA sites (17) . Alternatively, the activation of PKA could cause the inhibition of PP1 via increased phosphorylation of regulatory proteins, such as dopamine and cAMP-regulated phosphoprotein DARPP-32 (18) and the PP1 inhibitory protein I-1, leading to the decreased dephosphorylation of NMDAR subunits by PP1 (19) and up-regulation of NMDAR currents. To evaluate these potential signaling mechanisms, we examined the effect of SKF81297 on NMDARs in the presence of PKA or PP1 inhibitors.
As shown in Fig. 2 A and B , dialysis with the PKA inhibitory peptide PKI 6 -22 (20 M) failed to block the SKF81297-induced increase of NMDAR currents (101.3 Ϯ 9.7% of control modulation, n ϭ 15). The effect of SKF81297 was also intact in the presence of the membrane-permeable PKA inhibitory peptide, myristoylated PKI 14 -22 (0.2 M, 91.9 Ϯ 4.3% of control modulation, n ϭ 10, Fig. 2B ). Moreover, bath application of the PP1 inhibitor OA (0.1 M) did not affect the ability of SKF81297 to enhance NMDAR currents (Fig. 2C) . As summarized in Fig. 2D , inhibiting PP1 catalytic activity with external or internal application of OA failed to block the SKF81297 enhancement of NMDAR currents (external OA: 109.2 Ϯ 2.3% of control modulation, n ϭ 8; internal OA: 102.2 Ϯ 1.9% of control modulation, n ϭ 23). The effect of SKF81297 on NMDAR currents was also unaffected when -containing: 0.32 Ϯ 0.07, n ϭ 32). As shown in Fig. 3 A and B , SKF81297 completely lost the ability to enhance NMDAR currents in the neuron treated with the Ca 2ϩ -free solution. We then dialyzed neurons with a high concentration (10 mM) of BAPTA, a potent and rapid Ca 2ϩ chelator, and examined D 1 modulation of NMDAR currents under this condition. Dialysis with high BAPTA reduced the inactivation of NMDAR currents (I ss ͞ I peak ; high BAPTA: 0.42 Ϯ 0.06, n ϭ 13; low BAPTA: 0.32 Ϯ 0.07, n ϭ 32), and substantially attenuated the effect of SKF81297 on NMDAR currents (Fig. 3C) . In a set of neurons we tested (Fig. 3D) , the enhancing effect of D 1 on NMDAR currents was eliminated under the Ca 2ϩ -free condition (Ϫ6.0 Ϯ 2.0% of control modulation, n ϭ 7) and was signif- The binding of Ca 2ϩ ͞CaM to the NR1 subunit is thought to underlie Ca 2ϩ inactivation of NMDARs (23) (24) (25) . Thus, we examined the role of CaM in D 1 modulation of NMDAR currents in PFC pyramidal neurons. Intracellular infusion of active CaM (10 M) caused more inactivation of NMDA-evoked currents (I ss ͞I peak ; with CaM, 0.22 Ϯ 0.06, n ϭ 9; without CaM: 0.32 Ϯ 0.07, n ϭ 32), and substantially blocked the SKF81297-induced potentiation of NMDAR currents (Fig. 4 A and B) . On the other hand, inclusion of the CaM antagonist CDZ (20 M) or the CaM inhibitory peptide MLCK peptide (26) in patch electrodes reduced the inactivation of NMDAR currents (I ss ͞I peak ; with CaM inhibitors: 0.41 Ϯ 0.04, n ϭ 19; without CaM inhibitors: 0.32 Ϯ 0.07, n ϭ 32), and markedly attenuated the enhancing effect of SKF81297 (Fig. 4C) . In a sample of neurons we tested (Fig. 4D) , the SKF81297 enhancement of steady-state NMDAR currents was significantly (P Ͻ0.001, ANOVA) smaller in neurons dialyzed with CaM (39.4 Ϯ 4.5% of control modulation, n ϭ 7), CDZ (40.6 Ϯ 4.2% of control modulation, n ϭ 14), or the CaM inhibitory peptide MLCK peptide (33.8 Ϯ 3.6% of control modulation, n ϭ 12).
We also examined the effect of SKF81297 on NMDAR currents in the presence of the Ca 2ϩ ͞CaM-dependent protein kinase II inhibitor KN-93 or the calcineurin inhibitor CsA, to determine whether these Ca 2ϩ -dependent enzymes were involved. The presence of KN-93 (10 M) or CsA (50 M) failed to reduce the SKF81297-induced potentiation of NMDAR currents (Fig. 4D, KN-93: 105.8 Ϯ 3 .6% of control modulation, n ϭ 14; CsA: 104.4 Ϯ 2.7% of control modulation, n ϭ 5). Collectively, these results suggest that the D 1 potentiation of NMDAR currents in PFC pyramidal neurons is caused by suppression of Ca 2ϩ ͞CaM-dependent inactivation of NMDARs.
The D 1 Enhancement of NMDAR Currents in PFC Pyramidal Neurons Is
Through a Mechanism Involving PKC. Previous studies in hippocampal neurons have shown that PKC activation enhances Ca 2ϩ ͞ CaM-dependent inactivation of NMDAR channels (27) , presumably because of a phosphorylation-dependent regulation of the interactions between NMDAR subunits, CaM, or other postsynaptic density proteins (27) . We therefore examined the role of PKC in D 1 modulation of NMDAR currents in PFC pyramidal neurons. As shown in Fig. 5 A and B , intracellular infusion of the PKC inhibitory peptide PKC 19 -36 (4 M) substantially diminished the SKF81297-induced potentiation of NMDAR currents. In the presence of bisindolylmaleimide (1 M), a membrane-permeable selective PKC inhibitor, SKF81297 also had a much smaller effect on NMDAR currents (Fig. 5C ). As summarized in Fig. 5D , the SKF81297 enhancement of steady-state NMDAR currents was significantly (P Ͻ0.001, ANOVA) reduced in neurons dialyzed with PKC 19 -36 (29.3 Ϯ 5.3% of control modulation, n ϭ 17) or treated with bisindolylmaleimide (43.9 Ϯ 4.2% of control modulation, n ϭ 21).
Given the involvement of both Ca 2ϩ ͞CaM and PKC in the D 1 modulation of NMDAR currents in PFC pyramidal neurons, we examined their possible interconnections. It has been shown that Ca 2ϩ ͞CaM competes with PKC for binding to A-kinase anchoring protein (AKAP) 79, releasing the inhibited PKC from its association with the anchoring protein (28) . Thus, we dialyzed neurons with a peptide AKAP (29) to disrupt the interaction of PKC with AKAP79, followed by the examination of SKF81297 effects on NMDAR currents. As shown in Fig. 6 A and B , the SKF81297-induced potentiation of NMDAR currents was markedly reduced in neurons loaded with the AKAP 31-52 peptide (40 M, 43.6 Ϯ 4.1% of control modulation, n ϭ 15, P Ͻ0.001, ANOVA, Fig. 6D ). On the other hand, application of U73122 (1 M), a phospholipase C (PLC) inhibitor, failed to affect SKF81297 enhancement of NMDAR currents (Fig. 6C, 115 .8 Ϯ 6.1% of control modulation, n ϭ 4, Fig. 6D) , indicating that the D 1 regulation of NMDARs was independent of the PLC pathway.
The potential role of several other signaling molecules in the D 1 regulation of NMDARs in PFC pyramidal neurons was also examined. As summarized in Fig. 6D , the enhancing effect of SKF81297 was intact in the presence of the inositol-1-4-5-triphosphate receptor antagonist heparin (2 mg͞ml, 103.5 Ϯ 5.5% of control modulation, n ϭ 4), the phosphoinositide 3-kinase inhibitor wortmannin (3 M, 78.3 Ϯ 6.7% of control modulation, n ϭ 12), or the broad-spectrum protein tyrosine kinase inhibitor genistein (100 M, 87.1 Ϯ 4.0% of control modulation, n ϭ 16), indicating the lack of involvement of these molecules. Taken together, these results suggest that the D 1 potentiation of NMDAR currents in PFC pyramidal neurons is through a mechanism involving PKC that is regulated by CaM.
Discussion
Because the schizophrenia-like behaviors induced by administration of NMDAR antagonists (10, 11) or NMDAR knockdown (12) have implicated NMDARs in mental disorders associated with PFC dysfunction, it is conceivable that D 1 receptors may influence PFC functions through the regulation of NMDAR channels. In agreement with this, D 1 and NMDARs are enriched in dendritic spines (30) (31) (32) (33) . This synaptic organization enables interactions between dopamine and glutamate signaling in the same neuron. In this study, we demonstrated that activation of D 1 receptors significantly enhanced NMDAR currents in acutely dissociated PFC pyramidal neurons, consistent with previous findings on D 1 potentiation of NMDAR-mediated excitatory postsynaptic currents in PFC slices (34, 35) , and D 1 increase of NMDAR currents in medium spiny neostriatal neurons (36) . Our data suggest that the postsynaptic NMDAR is a potential key target of D 1 receptors. On the other hand, application of NMDA in cultured striatal neurons increases the recruitment of D 1 receptors to dendritic spines in a Ca 2ϩ -dependent manner (13) , suggesting that NMDARs can also regulate D 1 signaling. The reciprocal positive interactions between D 1 and NMDAR channels could play a significant role in regulating the cognitive and emotional status.
NMDAR channel activity can be regulated by a wide array of extracellular agents, including Mg 2ϩ , glycine, and Zn 2ϩ (37) , intracellular agents like Ca 2ϩ and CaM (21, 24) , and protein kinases͞phosphatases, such as PKA, PKC, and PP1 (19, 38, 39) . Our results show that the D 1 enhancement of steady-state NMDAR currents in PFC pyramidal neurons is through the suppression of Ca 2ϩ ͞CaM-dependent inactivation of NMDAR channels, but not via the classical PKA͞PP1 cascade as found in striatal neurons (36, 40) . Unlike the D 4 -mediated downregulation of NMDAR channels in PFC pyramidal neurons (16) , Ca 2ϩ ͞CaM-dependent protein kinase II is not involved in this D 1 action. Inhibiting PKC activity or disrupting PKC association with its anchoring protein AKAP79 attenuated the D 1 effect on NMDAR channels, suggesting the involvement of PKC in this modulation. Ca 2ϩ entry from NMDAR channels may regulate NMDAR inactivation by two mechanisms. One is through CaM binding to NR1 subunits directly (23, 24) . The other is through CaM competing with PKC for binding to AKAP79, leading to the release and disinhibition of PKC (28) and PKC-dependent potentiation of NMDAR inactivation (27) . By inhibiting Ca 2ϩ ͞ CaM through an unknown mechanism, activation of D 1 receptors suppresses the NMDAR inactivation, resulting in an enhanced steady-state NMDAR current. Given the key role of D 1 and NMDARs in schizophrenia and other neuropsychiatric disorders, the present results provide a possible cellular mechanism that could underlie the D 1 regulation of cognitive functions associated with PFC.
